亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

美羅培南對(duì)照品及雜質(zhì)快速優(yōu)惠供應(yīng)

 
 
單價(jià) 1000.00 / 支對(duì)比
銷量 暫無(wú)
發(fā)貨 廣東深圳市預(yù)售,付款后30天內(nèi)
庫(kù)存 1支起訂1支
品牌 TRC/TLC/USP/EP/LGC/Simson/MC
型號(hào) 96036-03-2
規(guī)格 10mg,25mg,50mg,100mg
過(guò)期 長(zhǎng)期有效
更新 2014-03-17 22:38
 

深圳佰森生物科技有限公司

企業(yè)會(huì)員第13年
資料未認(rèn)證
保證金未繳納
  • 廣東-深圳市
  • 上次登錄 2014-07-22
  • 林曉曉 (女士)   銷售工程師
詳細(xì)說(shuō)明

深圳菲斯生物科技有限公司主要為全國(guó)各大醫(yī)藥生產(chǎn)和研發(fā)企業(yè)、檢驗(yàn)機(jī)構(gòu)、科研院校等提供進(jìn)口標(biāo)準(zhǔn)品、中檢所對(duì)照品、醫(yī)藥雜質(zhì)對(duì)照品、醫(yī)藥中間體等,并為客戶提供醫(yī)藥技術(shù)開(kāi)發(fā)、委托代理研發(fā)、定制合成與分離等服務(wù)的高科技企業(yè),擁有完整、科學(xué)的質(zhì)量管理體系。

QQ:511195443    聯(lián)系電話:0755-29167321-602  手機(jī):18925202235     

聯(lián)系人:林曉曉   郵箱:elita.lin@phystandard.*

美羅培南Meropenem


    Meropenem Trihydrate
    Meropenem Dimer Impurity

(4R,5S,6S)-3-[[(3S,5S)-5-[(Dimeth-ylamino)carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid trihydrate
[CAS # 119478-56-7]


Meropenem *bination with Sodium Carbonate

美羅培南雜質(zhì)A,包裝為10mg

美羅培南雜質(zhì)B,包裝為10mg


舉報(bào)收藏 0評(píng)論 0
更多>本企業(yè)其它產(chǎn)品
凝血酸、利伐沙班雜質(zhì)對(duì)照品快速優(yōu)惠供應(yīng) 甲糖寧、維達(dá)列汀雜質(zhì)對(duì)照品快速優(yōu)惠供應(yīng) 甲巰咪唑、***雜質(zhì)對(duì)照品快速優(yōu)惠供應(yīng) 睪酮庚酸鹽、阿西替尼雜質(zhì)對(duì)照品快速優(yōu)惠供應(yīng) 噻托溴銨一水合物、維莫德吉雜質(zhì)對(duì)照品快速優(yōu)惠供應(yīng) 度他雄胺對(duì)照品及雜質(zhì)快速優(yōu)惠供應(yīng) 泰妙菌素、利匹韋林雜質(zhì)對(duì)照品快速優(yōu)惠供應(yīng)
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |